Navigation Links
Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
Date:10/2/2008

uss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. These factors include:

-- decisions by government and third party reimbursement agencies as to

the rate of reimbursement for our products, or whether reimbursement

will be allowed;

-- the impact of international currency fluctuations on our cash flows and

operating results;

-- the impact of technological innovation and competition; acceptance of

our products by physicians and patients;

-- our intellectual property and the ability to prevent competitors from

infringing our rights;

-- the effect of government regulation, including when and if we receive

approval for marketing products in the United States;

-- the results of clinical trials; and

-- our continued losses and the possible need to raise additional capital

in the future.

We cannot assure you that our clinical trial will produce favorable results, that third-party payers will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses, nor can we assure you that we will timely obtain, or even succeed at all at obtaining, a specific "listed" CPT code from the AMA for Urgent PC treatments. We further cannot assure you that reimbursement or other issues will not further impact our fiscal 2009 results.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer,

952.426.6140

EVC Group

Doug Sherk/Dahlia Bailey (Investors)

415.896.6820

Chris Gale (Media)

646.201.5431


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
3. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
4. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
7. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
8. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. First European Patients Treated With the Percutaneous MitraClip(R) System
11. Trius Doses First Patient in Antibacterial Phase 2 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , September 2, 2014 ... including patients, quality of life and treatment satisfaction [ ... 2 ]   ... Congress 2014, 02 September 2014, Barcelona, Spain ... of the PREvention oF thromboembolic events-European Registry in Atrial ...
(Date:9/2/2014)... YORK , September 2, 2014 ... WellPoint Inc. (NYSE: WLP ), Tekmira Pharmaceuticals ... ZTS ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,WellPoint Inc. Research Reports ,WellPoint Inc. ...
(Date:9/2/2014)... HOUSTON , Sept. 2, 2014  Cyberonics, ... results from the ANTHEM-HF clinical study.  Results of ... specialist during a major European cardiology congress and ... Failure show Autonomic Regulation Therapy (ART) in ... and impaired heart function is safe, improves the ...
Breaking Medicine Technology:One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5
... 20 Thomson Reuters, a global provider ... the newest version of its award-winning Clinical ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: ... hospital-based clinicians to access complete patient clinical ...
... VPHM ) third quarter financial results for 2010 ... before the open of the U.S. financial markets. ... webcast at 9:00 a.m. Eastern Time on the same day. ... third quarter financial results and other business. ...
Cached Medicine Technology:Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010 2
(Date:9/2/2014)... September 02, 2014 On August 30, ... website titled “Why You Should Wash Your Face ... of the global population breathes air considered polluted by ... pollution lodge in the skin’s pores destroying its natural ... to free radicals that may cause cell damage, redness, ...
(Date:9/2/2014)... lay the groundwork for their own spread throughout the ... out tumor-welcoming signals, according to a new report by ... issue of Nature Communications , the researchers describe ... so-called signaling molecules released by breast cancer cells. These ... and lymph nodes to produce proteins called CCL5 and ...
(Date:9/2/2014)... Doheny HealthDay Reporter TUESDAY, ... is a driving force behind the rising rates of type ... at data from five national surveys spanning from 1976 through ... time could be explained by factors such as changing distribution ... investigators found that the prevalence of diabetes in men rose ...
(Date:9/2/2014)... (HealthDay News) -- A leading group of oncologists has ... form of advanced breast cancer. HER2-negative breast ... target the HER2 protein, the American Society of Clinical ... Almost 80 percent of women with advanced breast ... releasing this guideline, our aim is to improve both ...
(Date:9/2/2014)... ALEXANDRIA, VAThe latest research on sleep apnea, tonsillectomies, ... otolaryngic topics will be presented in Orlando, FL, ... OTO EXPO℠ of the American Academy of OtolaryngologyHead ... meeting of ear, nose, throat, head and neck ... research to be presented were released today, and ...
Breaking Medicine News(10 mins):Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2
... and the University of Florida Proton Therapy Institute have formed ... The announcement follows the approval of the first clinical study ... cancers in children younger than 3 years old. ... to receive proton therapy at the UF Proton Therapy Institute ...
... respiratory disease, often leading to disability or an increased ... Studies led by Deborah Young-Corbett, a faculty member ... specific types of sanding tools are highly effective in ... the industry,s usage of the available technology remains very ...
... -- The lives of almost 4 million women, newborns, ... year if well-established, affordable health care interventions reached 90 ... the national science academies of seven African countries. ... save lives, says the report, which calls on scientists, ...
... ... Texas , is sponsoring a new video contest inviting participants to describe why they are ... worth up to $15,000, and submitted videos will be shown on Austin Dental Spa’s website ... ...
... ... Self-service Kiosks and Pricing Transparency Patient Estimations. , ... Denver, CO (PRWEB) November 9, 2009 ... a partnership that provides patients more control when interacting with providers by understanding ...
... ... Ask4UFE to launch a podcast series that helps women suffering in silence understand their ... ... but they are life altering, says supermodel Beverly Johnson, during a new 3-part ...
Cached Medicine News:Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:Using science to save lives of mothers and children in Africa 2Health News:Using science to save lives of mothers and children in Africa 3Health News:Using science to save lives of mothers and children in Africa 4Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 2Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 3Health News:FHS Corp. Announces Partnership with Vecna Technologies 2Health News:New Series of Podcasts Highlight Supermodel's "Life-altering" Experience to Raise Awareness of Fibroid Treatment Options 2
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Designed to securely hold scleral plugs during insertion and removal. The cross action handle is designed to reduce hand fatigue while grasping plug....
For use with the Landers Vitrectomy Lens set (MVS 1079A). Shafts angled 45 degrees with curved grooved blades for holding the Landers vitrectomy lenses. Polished finish....
Ergotec Vetriretinal Instrument System. Ultra-fine angled tips (4 mm) with 20 gauge shaft. 25 mm in length. Overall length from rear rotation knob to tip....
Medicine Products: